biotech · Breast Cancer · Advanced Breast Cancer · PBYI
PUMA BIOTECHNOLOGY
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker PBYI. Primary therapeutic focus areas include Breast Cancer, Advanced Breast Cancer, HER2+ Metastatic Breast
10880 Wilshire Blvd, Los Angeles, CA 90024, US HQ
2010 Founded
257 Employees
Public company Type
PBYI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10880 Wilshire Blvd, Los Angeles, CA 90024, US
- Founded
- 2010
- Employees
- 257
- Programs
- 40
- Drugs
- 23
- Patents
- 1
Neratinib
Phase 2 · small molecule · Metastatic Prostate Adenocarcinoma
Neratinib for Metastatic Prostate Adenocarcinoma is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Internal code 20-659
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PUMA BIOTECHNOLOGY, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic Prostate Adenocarcinoma
- Status
- terminated
- Trials
- 1